ENXTBR:UCBPharmaceuticals
What UCB (ENXTBR:UCB)'s First EU-Approved TK2d Therapy Kygevi Means For Shareholders
UCB has received European Union approval for Kygevi to treat thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12, marking the first EU-authorized therapy for this rare genetic condition.
The decision builds on prior FDA approval and retrospective data showing a very large reduction in risk of death versus untreated TK2d patients, underscoring Kygevi’s medical significance for a small but highly underserved population.
We’ll now examine how Kygevi’s first-in-EU...